Research Topics
| S J GoldsmithSummaryAffiliation: Cornell University Country: USA Publications
| Collaborators
|
Detail Information
Publications
To ablate or not to ablate: issues and evidence involved in 131I ablation of residual thyroid tissue in patients with differentiated thyroid carcinomaStanley J Goldsmith
Department of Nuclear Medicine and Molecular Imaging, Weill Medical College of Cornell University, New York Presbyterian Hospital Weill Cornell Medical Center, New York, NY 10065, USA
Semin Nucl Med 41:96-104. 2011....- An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicineS J Goldsmith
New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY 10065, USA
Q J Nucl Med Mol Imaging 54:574-81. 2010..This field is in continuous evolution and this overview highlights the role of radiolabelled antibodies in research and clinical setting... - Radionuclide imaging of thoracic malignanciesStanley J Goldsmith
Weill Medical College, Cornell University, 1300 York Avenue, New York, NY 10021, USA
Thorac Surg Clin 14:95-112. 2004..Both methods have incremental value over CT imaging in selecting patients who have solitary pulmonary nodules for invasive biopsy or for thoracotomy... - Radioimmunotherapy of lymphoma: Bexxar and ZevalinStanley J Goldsmith
Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Cornell College of Medicine, New York, NY 10065, USA
Semin Nucl Med 40:122-35. 2010..This article reviews the basis for dose selection, the nuclear medicine procedures involved, the results obtained to date, and issues related to patient and staff safety... - Update on nuclear medicine imaging of neuroendocrine tumorsStanley J Goldsmith
Radiology and Medicine, Weill Medical College of Cornell University, Nuclear Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, New York, NY 10065, USA
Future Oncol 5:75-84. 2009..Early results and issues pertaining to availability are reviewed. The identification of the 'best' tracer will depend on multiple factors... - Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applicationsStanley J Goldsmith
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Nucl Med 39:2-10. 2009..In this work, we review the features of each of these agents and discuss the issues involved in their use as radiopharmaceuticals for the identification of inflammation and/or infection... - Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumorPeter M Smith-Jones
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY 10021, USA
J Nucl Med 44:610-7. 2003..In addition, because J591 and J415 mAbs are specific to PSMA(ext), thus targeting viable tumor, these immunoconjugates are better candidates for targeted radioimmunotherapy than are antibodies targeting PSMA(int)... - Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones
Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 48:342-8. 2007..Two patients had objective responses of 1 and 42.4+ months, respectively. RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses... - FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu
Department of Radiology, Division of Nuclear Medicine, Mount Sinai School of Medicine, New York, New York, USA
Cancer 107:2678-87. 2006.... - Improving insight into radiobiology and radionuclide therapyStanley J Goldsmith
New York Weill Cornell Medical Center, New York, New York, USA
J Nucl Med 45:1104-5. 2004 - The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao
James Buchanan Brady Department of Urology, The New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Urol Oncol 20:211-8. 2002..Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone... - Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphomaLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 94:879-88. 2002.... - Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigenNeil H Bander
Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Oncol 30:667-76. 2003..Imaging of patients after they have received radiolabeled J591 demonstrates excellent tumor targeting... - Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomographyL Kostakoglu
Department of Radiology, Division of Nuclear Medicine, The New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021 USA
Clin Lymphoma 1:67-74; discussion 75-6. 2000..Published results suggest that FDG-PET is superior to (67)Ga imaging and may be equal or superior to CT for the detection of nodal as well as extranodal involvement in lymphoma... - Lymphoma imaging: nuclear medicineLale Kostakoglu
Department of Radiology, Division of Nuclear Medicine, The New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY, USA
Cancer Treat Res 131:363-412. 2006 - Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Oncol 22:2522-31. 2004..5 mCi/m(2). Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of (90)Y-J591 in the treatment of patients with PC... - Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik
Center for Lymphoma and Myeloma, Division of Hematology/Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
Cancer 106:616-22. 2006..CONCLUSIONS: Most patients with progressive disease after treatment with iodine I-131 tositumomab were able to receive subsequent therapy, including cytotoxic chemotherapy and stem cell transplantation... - Clinical role of FDG PET in evaluation of cancer patientsLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Cornell Medical Center, 525 E 68th St, Starr No. 221, New York, NY 10021, USA
Radiographics 23:315-40; quiz 533. 2003..The high sensitivity and high negative predictive value of FDG PET in most malignant tumors enable this technique to play an even greater role in tumor management at initial staging and follow-up... - Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA
J Clin Oncol 25:540-7. 2007..This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response... - Oedipus or Orestes? Homosexual men, their mothers, and other women revisitedS J Goldsmith
Weill Medical College of Cornell University, USA
J Am Psychoanal Assoc 49:1269-87. 2001..Finally, the implications of this model for psychotherapeutic endeavors with homosexual men are considered... - PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagusLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College, Cornell University, New York, New York, USA
J Nucl Med 45:56-68. 2004..Therefore, (18)F-FDG PET may change patient management and lead to improved survival for a selected group of patients with carcinoma of the head and neck and of the esophagus... - Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
Cancer 116:1075-83. 2010..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy... - Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander
Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E 300, New York, NY 10021, USA
J Clin Oncol 23:4591-601. 2005.... - PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's diseaseLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
J Nucl Med 43:1018-27. 2002.... - Possible axonal regrowth in late recovery from the minimally conscious stateHenning U Voss
Citigroup Biomedical Imaging Center and Department of Radiology, Weill Medical College of Cornell University, and NeuroOncology Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Clin Invest 116:2005-11. 2006..We propose that axonal regrowth may underlie these findings and provide a biological mechanism for late recovery. Our results are discussed in the context of recent experimental studies that support this inference... - Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphomaJohn P Leonard
Oncology Services, New York Presbyterian Hospital, New York Weill Cornell Medical Center, Starr Pavilion, Room ST 340, 520 East 70th Street, New York, NY 10021, USA
Cancer Invest 21:241-52. 2003..Further studies are needed, however, to determine if the differences in the pharmacology of 131I and 90Y are clinically relevant... - Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander
Department of Urology, Division of Nuclear Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA
J Urol 170:1717-21. 2003.... - Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula
Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
Clin Cancer Res 11:7195s-7200s. 2005..Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591 and 90Y-J591 monoclonal antibodies (mAb) on myelotoxicity... - Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude miceShankar Vallabhajosula
Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
Prostate 58:145-55. 2004..Radiolabeled J591 monoclonal antibody (MAb) binds with high affinity to an extracellular epitope of PSMA and localizes specifically in PSMA positive LNCaP tumors in vivo... - Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, USA
J Nucl Med 46:634-41. 2005..The radiation dosimetry of 90Y-J591 was estimated based on both 111In and 177Lu data to validate the usage of 111In as a chemical and biologic surrogate for 90Y... - PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptakeLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 E 68th St, Starr No 221, New York, NY 10021, USA
Radiographics 24:1411-31. 2004.... - Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigenDavid M Nanus
Department of Medicine, Joan and Stanford I Weill Medical College of Cornell University, New York, NY 10021, USA
J Urol 170:S84-8; discussion S88-9. 2003..Monoclonal antibody (mAb) J591 recognizes the extracellular domain of PSMA. The current status of clinical trials using mAb J591 is reviewed... - Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
J Nucl Med 46:850-8. 2005.... - The role of FDG-PET imaging in the management of lymphomaLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Adv Hematol Oncol 2:115-21. 2004.... - Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
J Clin Oncol 23:5696-704. 2005..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma... - Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancerM C Graham
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 5:1307-18. 1999..These results suggest that a single 24-h measurement of retained activity would allow individualized dosing and an improved therapeutic index relative to fixed dosing schema. Repetitive dosing is required to increase palliation... - In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigenP M Smith-Jones
Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York 10021, USA
Cancer Res 60:5237-43. 2000..e., the exposed extracellular domain of PSMA). Both J415 and J591 are promising mAbs for the targeting of viable PSMA-expressing tissue with diagnostic and therapeutic metallic radionuclides... - 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinomaLale Kostakoglu
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
J Nucl Med 44:224-39. 2003..In this review, we discuss the role of (18)F-FDG PET in evaluating the response to therapy and the impact of this information on patient management... - PET imaging of leptin biodistribution and metabolism in rodents and primatesGiovanni Ceccarini
Laboratory of Molecular Genetics, Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA
Cell Metab 10:148-59. 2009.... - Thyroid uptake of liquid versus capsule 131I tracers in hyperthyroid patients treated with liquid 131IJ N Rini
The New York Hospital Cornell Medical Center, Division of Nuclear Medicine, New York, USA
Thyroid 9:347-52. 1999..Patients whose 131I therapy was based on the uptake of a capsule tracer received a higher than intended amount of radiation to the thyroid gland... - Investigation of the role of the base in the synthesis of [18F]FLTMakiko Suehiro
Citigroup Biomedical Imaging Center, Weill Medical College of Cornell University, 516 East 72nd Street, New York, NY 10021, USA
Appl Radiat Isot 65:1350-8. 2007..When the precursor-to-base ratio was optimal, an overall [18F]FLT yield of 30-40% was achieved even if the precursor amount was as small as 8-13 mg... - Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Genitourin Cancer 4:249-56. 2006..Additional studies are under way to better define the activity of radiolabeled antibody therapy as well as the role for fractionated therapy and combination approaches with taxane-based chemotherapy... - FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford
Centre for Lymphoma and Myeloma, Division of Haematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 49:719-26. 2008..Our findings support a potential role for preoperative FDG-PET in consideration of the need for splenectomy in these settings... - Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse modelRobert M Sharkey
Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Ave, Belleville, NJ 07109, USA
Radiology 246:497-507. 2008..To prospectively determine if a bispecific monoclonal antibody (MoAb) pretargeting method with a radiolabeled hapten peptide can depict small (<0.3 mm in diameter) microdisseminated human colon cancer colonies in the lungs of nude mice... - Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher
University of Rochester School of Medicine, James P Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
J Clin Oncol 23:7565-73. 2005.... - Current status of radiolabeled peptides in nuclear medicine diagnosis and therapyStanley J Goldsmith
Semin Nucl Med 32:78. 2002